Cutting edge: dendritic cells require maturation via CD40 to generate protective antitumor immunity

MF Mackey, JR Gunn, C Maliszewski… - The Journal of …, 1998 - journals.aai.org
MF Mackey, JR Gunn, C Maliszewski, H Kikutani, RJ Noelle, RJ Barth
The Journal of Immunology, 1998journals.aai.org
A critical role for CD40/CD154 interactions in the generation of protective cell-mediated
tumor immunity has been demonstrated previously. Herein, we show that the failure to
generate systemic tumor immunity in the absence of CD40/CD154 interactions correlates
with an inhibition of Th1-type cytokine production following tumor vaccination. Furthermore,
protective antitumor responses can be restored in CD40-deficient mice by the
coadministration of CD40+/+ but not CD40−/− dendritic cells (DCs) with tumor Ag …
Abstract
A critical role for CD40/CD154 interactions in the generation of protective cell-mediated tumor immunity has been demonstrated previously. Herein, we show that the failure to generate systemic tumor immunity in the absence of CD40/CD154 interactions correlates with an inhibition of Th1-type cytokine production following tumor vaccination. Furthermore, protective antitumor responses can be restored in CD40-deficient mice by the coadministration of CD40+/+ but not CD40−/− dendritic cells (DCs) with tumor Ag, suggesting that CD40 is critical for the maturation and function of DCs in vivo. Finally, we demonstrate that an IL-12-transduced but not a mock-transduced tumor vaccine induces systemic tumor immunity in anti-CD154-treated and CD154-deficient mice. These data suggest that impaired antitumor responses in the absence of CD40/CD154 interactions are the result of a lesion in APC function, namely IL-12 production, and that CD40 plays a critical role in the maturation of DCs in vivo.
journals.aai.org